Over the past decade, genome-wide association studies (GWAS) have identified thousands of single-nucleotide polymorphisms (SNPs) that are associated with disease risk, establishing a useful library of genomic regions that are involved in the genesis and progression of human disease. The majority of SNPs are known to localize to non-coding regions of the genome, where they are generally thought to map to distal transcriptional enhancers. The presence of clinically relevant mutations in enhancers adds a layer of difficulty to elucidating their effects. However, as illustrated by two new studies published in this issue of Cell (Gao et al., 2018; Hua et al., 2018) , efforts to untangle the molecular pathways involved can both provide insight into human disease and reveal novel modes of gene regulation.
Both studies begin with an SNP, rs11672691, that is associated not only with predisposition to prostate cancer (PCa) but also with aggressiveness (Amin Al Olama et al., 2013; Shui et al., 2014) . The mutation is located on chromosome 19 within an intron of a noncoding RNA, PCAT19, that is more highly expressed in PCa tumors than in normal prostate-as is a neighboring gene, CEACAM21, located 100 kb away (Figure 1 ). The immediate questions, then, are (1) does the mutation affect an enhancer for PCAT19 and/or CEACAM21; and (2) what function does the lncRNA play in development of PCa? Gao et al. (2018) find that the region is enriched for enhancer-associated histone modifications and determine that the risk allele, involving a mutation of an A to a G, creates a higher-affinity binding site for the transcription factor HOXA2 ( Figure 1B ). This is verified elegantly via HOXA2 ChIP in a PCa cell line, 22Rv1, that is heterozygous for the risk allele. Subsequently, the authors show that knockdown of HOXA2 reduces expression of both the PCAT19 and CEACAM21 genes. Moreover, CRISPR/Cas9-mediated genome editing of heterozygous 22Rv1 cells to homozygosity for the risk allele (G/G) results in increased binding of HOXA2 and in increased expression of PCAT19 and CEACAM21, while editing to homozygosity for the non-risk allele (A/A) has the opposite effects.
The implication of HOXA2 in mediating the oncogenic effects of the rs11672691 risk allele is completely unanticipated, and so Gao et al. (2018) go on to show that HOXA2 knockdown in 22Rv1 cells reduces cell growth, migration, and invasion in in vitro assays and tumor burden in mouse models. Importantly, they also find higher HOXA2 expression in human tumors compared to normal prostate tissue along with increased risk of recurrence and shorter survival in patients exhibiting higher HOXA2 expression. Their work implicates HOXA2 in PCa progression and specifically as a direct mediator of increased gene expression at the PCAT19/CEACAM21 locus associated with the A-to-G mutation at rs11672691. Hua et al. (2018) , meanwhile, examine the same locus in the same context and arrive at completely distinct, but complementary, conclusions. In their motif analysis of the rs11672691 region, they focus instead on a binding site for the tumor suppressor NKX3.1, which is often deleted in PCa ( Figure 1A ). Using the same heterozygous 22Rv1 cell line, they show that the A-to-G mutation reduces the affinity for this factor; moreover, they show that an additional PCa-associated SNP located 36 bp away similarly affects binding of the transcription factor YY1.
Like Gao et al. (2018) , Hua et al. (2018) were also interested in how the SNP influences expression of the PCAT19 lncRNA. PCAT19 occurs in two isoforms in prostate tumors, and the rs11672691 SNP actually resides within the promoter region of the shorter of these (PCAT19-short). Upon close examination, they find that the A-to-G mutation results in the downregulation of the short form in favor of the longer form (PCAT19-long), the promoter of which is located 40 kb away ( Figure 1B) . Knockdown of NKX3.1 or YY1 in cells homozygous for the non-risk (A/A) allele similarly increases PCAT19-long expression at the expense of PCAT19-short. The authors couple this with evidence from reporter-gene and 3C assays to propose that the mutation converts the PCAT19-short promoter into a distal PCAT19-long enhancer.
Additional experiments demonstrate that knockdown of the PCAT19-long transcript results in decreased cell growth, migration, and invasion as assayed in multiple PCa cell lines, while overexpression increases proliferation. RNA-seq reveals 113 genes upregulated in the knockdown, which correlate with PCa aggression in a TCGA cohort. Finally, Hua et al. (2018) show that the PCAT19-long lncRNA associates with HNRNPAB, the knockdown of which in turn upregulates the genes affected by PCAT19-long ( Figure 1B) . Thus, the rs11672691 SNP modulates a transcriptional switch in PCAT19 isoforms, resulting in preferential expression of a form that regulates downstream genes via a complex with HNRNPAB.
The two studies suggest a model in which transcription factors-one a tumor suppressor, the other oncogeniccompete for binding to a control element that can switch between promoter and enhancer function to govern the isoform of a lncRNA, which in turn contributes to prostate cancer progression. The mutation within this region tips the balance in favor of the oncogenic HOXA2 and enhancermediated expression of PCAT19-long.
The behavior of the SNP region could inform an important current problem in gene regulation: the distinction (or lack thereof) between gene promoters and distal enhancers. This distinction has become muddled based on observations of transcription initiation at most or all enhancers (Andersson et al., 2015; Kim and Shiekhattar, 2015) as well as a recent study that characterized a set of gene promoters that also act as enhancers of neighboring genes (Dao et al., 2017) . In this context, the PCAT19-short promoter provides a unique system in which a regulatory sequence can be toggled between promoter and enhancer function, which could be leveraged to gain insight into the characteristics that define both. Recent studies in Drosophila suggest that levels and directionality of transcription are better arbiters of enhancer versus promoter activity than the epigenomic modifications that are normally used for that purpose (Mikhaylichenko et al., 2018 , Henriques et al., 2018 . It will therefore be interesting to determine the nature of transcripts originating from the rs11672691 SNP region from either allele and/or upon manipulation of the relevant factors. More generally, is the competition between NKX1.3 and HOXA2 at this region a feature of control elements for other genes involved in PCa?
The PCAT19 lncRNA also poses intriguing questions. Do the two isoforms take up distinct secondary structures that lead to divergent function, or does the additional sequence in the long form mediate the HNRNPAB interaction independently? HNRNPAB itself occurs in multiple isoforms that are known to interact with different populations of RNA (Nguyen et al., 2018) ; with which form does PCAT19-long interact? How does the complex find its targets, and once there, how does it work to downregulate gene expression? The answers to these questions will not only inform mechanisms of oncogenesis but also provide potential new targets for therapy.
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